Lilly's Covid-19 partner AbCellera is taking a new antibody into the clinic in the hopes it can tackle all variants
As the virus behind the Covid-19 pandemic continues to mutate into several variants of concern, the company behind Eli Lilly’s bamlanivimab antibody treatment is looking to stay ahead of the curve.
AbCellera is pushing forward with a new monoclonal antibody candidate for Covid-19 that it says can neutralize all currently known variants, moving the program known as LY-CoV1404 into its first clinical trials, the Vancouver-based biotech said Tuesday morning. The program will join Lilly’s ongoing Blaze-4 study where it will be evaluated in mild to moderate Covid-19 cases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.